# Study of Arimoclomol in Inclusion Body Myositis (IBM)

> **NCT02753530** · PHASE2 · COMPLETED · sponsor: **ZevraDenmark** · enrollment: 152 (actual)

## Conditions studied

- Inclusion Body Myositis

## Interventions

- **DRUG:** Arimoclomol
- **OTHER:** Placebo

## Key facts

- **NCT ID:** NCT02753530
- **Lead sponsor:** ZevraDenmark
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2017-08-16
- **Primary completion:** 2021-01-11
- **Final completion:** 2021-01-11
- **Target enrollment:** 152 (ACTUAL)
- **Last updated:** 2023-05-10

## Collaborators

- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02753530

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02753530, "Study of Arimoclomol in Inclusion Body Myositis (IBM)". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT02753530. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*